Clinical Momentum Leverage Medicenna's late-stage focus on glioblastoma with Bizaxofusp and the PD-1 x IL-2 bispecific to pursue partnerships or co-development deals with oncology CROs, pharma companies, and academic medical centers actively seeking innovative brain cancer therapies and high-need immunotherapies.

Rare Disease & Autoimmune Targeting Explore collaboration opportunities around autoimmune and chronic inflammatory diseases where Medicenna has early programs, positioning their Superkine platforms for unmet needs in asthma, COPD, and related inflammatory conditions to expand sponsor interest and funding.

Innovative Platforms Position the Superkine BiSKIT and T-MASK platforms as differentiators for potential licensing, co-development, or strategic partnerships with companies seeking next-generation cytokine approaches for solid tumors and immune modulation.

Global Investor & Market Readiness Capitalize on ongoing investor and academic engagement (ASCO, AACR, Bloom Burton) to arrange sponsor-led briefings or patient-access programs, aligning potential buyers or partners with Medicenna’s near-term clinical readouts and Phase 3-ready assets.

Financial Levers Target strategic funding discussions and milestone-driven deals that align with Medicenna’s revenue range and $74M funding, proposing milestone-heavy collaborations, upfronts, and royalty arrangements tied to lead therapy performance in glioblastoma and other indications.